Judge Approves $158M Settlement of Texas Lawsuit
A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
- ‘Big Tobacco’ Moment for Cannabis: What Insurers Need to Know About Murray v. Cresco
- Snap, YouTube Settle School-Social Media Suit Ahead of Trial
- The Big Dog Is Off the Tech Porch: State Farm as ‘Next Gen Good Neighbor’
- Adapting Claim Investigations for AI-Driven Fraud